The use of antibodies that target NK cell inhibitory receptors directly, such as Monalizumab, which targets NKG2A and activates NK cells to kill tumor cells [55] and Lirilumab, an inhibitory KIR receptor inhibitor that specifically binds to the inhibitory KIR2DL1, -2, and -3 receptors with high affinity (and activates KIR2DS1 and -2 receptors), blocking KIR interaction with HLA-C and enhancing the NK cell killing of tumor cells [56]. The gene discussed is KLRC1; the disease is neoplasm.